Biodiversity Literature Repository

Submit to community
Liberated Data
Published May 31, 2017 | Version v1
Journal article Open

Effects of astaxanthin in mice acutely infected with Trypanosoma cruzi

Authors/Creators

Description

Contreras-Ortiz, José María Eloy, Barbabosa-Pliego, Alberto, Oros-Pantoja, Rigoberto, Aparicio-Burgos, José Esteban, Zepeda-Escobar, José Antonio, Hassan-Moustafa, Wael Hegazy, Ochoa-García, Laucel, Uxúa Alonso-Fresan, María, Tenorio Borroto, Esvieta, Vázquez-Chagoyán, Juan Carlos (2017): Effects of astaxanthin in mice acutely infected with Trypanosoma cruzi. Parasite (Paris, France) 24: 1-11, DOI: 10.1051/parasite/2017018, URL: https://doi.org/10.1051/parasite/2017018

Files

source.pdf

Files (5.0 MB)

Name Size Download all
md5:58f9d0529bd6a96fbacf72d5940b9b10
5.0 MB Preview Download

Linked records

Additional details

Identifiers

LSID
urn:lsid:plazi.org:pub:FFF9D052FFD6A96FFFCFFFD5940B9B10
URL
http://publication.plazi.org/id/FFF9D052FFD6A96FFFCFFFD5940B9B10

Has part
Taxonomic treatment: http://treatment.plazi.org/id/03C0A82AFFD4A96DFFBEFC1D95EC9C23 (URL)
Taxonomic treatment: http://treatment.plazi.org/id/03C0A82AFFD4A96DFFBEF8A691649975 (URL)
Taxonomic treatment: http://treatment.plazi.org/id/03C0A82AFFD5A96BFCE2F96895DC9975 (URL)
Taxonomic treatment: http://treatment.plazi.org/id/03C0A82AFFD2A96BFFBEFD4895C39FA3 (URL)
Figure: 10.5281/zenodo.20199087 (DOI)
Figure: 10.5281/zenodo.20199091 (DOI)
Figure: 10.5281/zenodo.20199093 (DOI)
Figure: 10.5281/zenodo.20199095 (DOI)
Figure: 10.5281/zenodo.20199099 (DOI)
Figure: 10.5281/zenodo.20199105 (DOI)

References

  • 1. Abdel-Mageed WM, Backheet EY, Khalifa AA, Ibraheim ZZ, Ross SA. 2012. Antiparasitic antioxidant phenylpropanoids and iridoid glycosides from Tecoma mollis. Fitoterapia, 83, 500-507.
  • 2. Acosta-Viana YK, Huchin-Cetz J, Jimenez-Coello M, Guzman-Marin E, Rosales-Encina JL. 2013. Antibody delivery into viable epimastigotes of Trypanosoma cruzi as a tool to study the parasite biology. Advances in Bioscience and Biotechnology, 4, 719-726.
  • 3. Antunez MI, Cardoni RL. 2000. IL-12 and IFN-g production, and NK cell activity, in acute and chronic experimental Trypanosoma cruzi infections. Immunology Letters, 71, 103-109.
  • 4. Aw TY. 1999. Molecular and cellular responses to oxidative stress and changes in oxidation-reduction imbalance in the intestine. American Journal of Clinical Nutrition, 70, 557-565.
  • 5. Barbabosa-Pliego A, Diaz-Albiter HM, Ochoa-Garcia L, Aparicio-Burgos E, Lopez-Heydeck SM, Velasquez-Ordonez V. 2009. Trypanosoma cruzi circulating in the southern region of the State of Mexico (Zumpahuacan) are pathogenic: a dog model. American Journal of Tropical Medicine and Hygiene, 81, 390-395.
  • 6. Bonney KM, Engman DM. 2008. Chagas heart disease pathogenesis: one mechanism or many? Current Molecular Medicine, 8, 510-518.
  • 7. Brener Z. 1962. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Revista do Instituto de Medicina Tropical de Sao Paulo, 4, 389-396.
  • 8. Cabeza MP, Chambo JG, Laguens RP. 1988. Differences in resistance to reinfection with low and high inocula of Trypanosoma cruzi in chagasic mice treated with nifurtimox and relation to immune response. Antimicrobial Agents and Chemotherapy, 32, 241-245.
  • 9. Camandaroba EL, Reis EA, Goncalves MS, Reis MG, Andrade SG. 2003. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Revista da Sociedade Brasileira de Medicina Tropical, 36, 201-209.
  • 10. Castro JA. 2000. Contribution of Toxicology to the problem of Chagas disease (American Trypanosomiasis). A year 2000 update. Biomedical and Environmental Sciences, 13, 271-279.
  • 11. Cencig S, Coltel N, Truyens C, Carlier Y. 2012. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or Am Bisome® in mice infected with Trypanosoma cruzi strains. International Journal of Antimicrobial Agents, 40, 527-532.
  • 12. Chew BP, Mathisona BD, Hayek MG, Massimino S, Reinhart GA, Park JS. 2011. Dietary astaxanthin enhances immune response in dogs. Veterinary Immunology and Immunopathology, 140, 199-206.
  • 13. Curty LG, Borges JC, Magalhaes CC, Pinheiro de Araujo H, Araujo ZA, Braga do Nascimento S, Machado MC, Rolim- Bernardino AM, De Souza Pereira MC, Cabral BS. 2016. Interactions between 4-aminoquinoline and heme: promising mechanism against Trypanosoma cruzi. International Journal for Parasitology: Drugs and Drug Resistance, 6, 154-164.
  • 14. Dhiman M, Coronado YA, Vallejo CK, Petersen JR, Ejilemele A, Nunez S, Zago MP, Spratt H, Garg NJ. 2013. Innate immune responses and antioxidant/oxidant imbalance are major determinants of Human Chagas disease. PLoS Neglected Tropical Diseases, 7(8), e2364.
  • 15. Diaz-Limay E, Escalante H, Jara AC. 2004. Niveles de parasitemia y alteraciones histopatologicas en Mus musculus BALB/c infectado con Trypanosoma cruzi obtenido de Panstrongylus chinai del Valle Chaman, La Libertad - Peru. Parasitologia Latinoamericana, 9, 153-158.
  • 16. Ditrich R, Schibel A, Hoffman I, Mueller A, Beckman M, Cupisti S. 2012. Influence of maternal smoking during pregnancy on oxidant status in amniotic fluid. In Vivo, 26, 813-818.
  • 17. Fassett GR, Coombes JS. 2012. Astaxanthin in cardiovascular health and disease. Molecules, 17, 2030-2048.
  • 18. Goto S, Kogure K, Abe K, Kimata Y, Kitahama K, Yamashita E, Terada H. 2001. Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid Astaxanthin. Biochimica et Biophysica Acta - Biomembranes, 1512(2), 251-258.
  • 19. Graziose R, Rojas-Silva P, Rathinasabapathy T, Dekock C, Grace MH, Poulev A, Lila MA, Smith P, Raskin I. 2012. Antiparasitic compounds from Cornus florida L. with activities against Plasmodium falciparum and Leishmania tarentolae. Journal of Ethnopharmacology, 142, 456-461.
  • 20. Gupta S, Jian-Jun W, Nisha JG. 2009. Oxidative stress in Chagas Disease. Interdisciplinary Perspectives on Infectious Diseases, 2009, 1-8.
  • 21. Hussein G, Sankawa U, Goto H, Matsumoto K, Watanabe H. 2006. Astaxanthin, a carotenoid with potential in human health and nutrition. Journal of Natural Products, 69, 443-449.
  • 22. Iwabayashi M, Fujioka N, Keitaro N, Ryo M, Takahashi H, Hibino S, Takahashi Y, Nishikawa K, Nishida M, Yonei Y. 2009. Efficacy and safety of eight-week treatment with astaxanthin in individuals screened for increased oxidative stress burden. Anti-Aging Medicine, 6(4), 15-21.
  • 23. James TN, Rossi MA, Yamamoto S. 2005. Postmortem studies of the intertruncal plexus and cardiac conduction system from patients with Chagas disease who died suddenly. Progress in Cardiovascular Diseases, 47, 258-275.
  • 24. Kavitha K, Kowshik J, Kiran KK, Basit BB, Nagini S. 2013. Astaxanthin inhibits NF-ĸB and Wnt/β- catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochimica et Biophysica Acta, 1830, 4433-4444.
  • 25. Kim HY, Koh HK, Doo-Sik K. 2010. Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-ĸBmediated signals in activated microglia. International Immunopharmacology, 10, 1560-1572.
  • 26. Kishimoto Y, Tani M, Uto-Kondo H, Iizuka M, Saita E, Sone H, Kurata H, Kondo K. 2010. Astaxanthin suppresses scavenger receptor expression and matrix metalloproteinase activity in macrophages. European Journal of Nutrition, 49(2), 119-126.
  • 27. Kuan-Hung L, Kao-Chang L, Wan-Jung L, Philip-Aloysius T, Thanasekaran J, Joen-Rong S. 2015. Astaxanthin, a carotenoid, stimulates immune responses by enhancing IFN-y and IL-2 Secretion in primary cultured lymphocytes in vitro and ex vivo. International Journal of Molecular Sciences, 17(44), 1-10.
  • 28. Kuhn RE, Vaughn RT, Herbst GA. 1975. The effect of BCG on the course of experimental Chagas' disease in mice. International Journal for Parasitology, 5, 557-560.
  • 29. Leite J, Oliveira A, Lombardi J, Filho J, Chiari E. 2006. Trypanocidal activity of triterpenes from Arrabidaea triplinervia and derivatives. Biological and Pharmaceutical Bulletin, 29, 2307-2309.
  • 30. Macao BL, Wilhelm FD, Coury PR, Pereira A, Backes P, Aloisio TM, Silva FT. 2007. Antioxidant therapy attenuates oxidative stress in chronic cardiopathy associated with Chagas disease. International Journal of Cardiology, 123, 43-49.
  • 31. Manning-Cela R, Cortes A, Gonzales-Rey E, Wesley CV, Swindle J, Gonzales A. 2001. LYT1 protein is required for efficient in vitro infection by Trypanosoma cruzi. Infection and Immunity, 73(11), 7356-7365.
  • 32. Maya J, Cassels B, Iturriaga-Vasquez P, Ferreira J, Faundez M, Galanti N. 2006. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comparative Biochemistry and Physiology, 146, 601-620.
  • 33. Meyers PS, Bligh D. 1981. Characterization of astaxanthin pigments from heat-processed crawfish waste. Journal of Agricultural and Food Chemistry, 29(3), 505-508.
  • 34. Nakao R, Nelson OL, Park JS, Mathison BD, Thompson PA, Chew BP. 2010. Effect of astaxanthin supplementation on inflammation and cardiac function in BALB/c mice. Anticancer Research, 30, 2721-2726.
  • 35. National Academic of Science. 2011. Guide for the Care and Use of Laboratory Animals, 8th edn.. National Academic Press: Washington DC.
  • 36. Navideh A, Chin PT. 2013. Effects of selected polysorbate and sucrose ester emulsifiers on the physicochemical properties of astaxanthin nanodispersions. Molecules, 18, 768-777.
  • 37. NORMA Oficial Mexicana NOM-062-ZOO-1995. 1995. Especificaciones y caracteristica zoosanitarias para el transporte de animales, sus productos y subproductos, productos quimicos, farmaceuticos, biologicos y alimenticios para uso en animales o consumo por estos. Mexico City, Mexico: Diario Oficial de la Federacion. http://dof.gob.mx/nota_detalle.php? codigo=4883147&fecha=16/10/1995
  • 38. NORMA Oficial Mexicana NOM-062-ZOO-1999. 1999. Especificaciones tecnicas para la produccion, cuidado y uso de los animales de laboratorio. Mexico City, Mexico: Diario Oficial de la Federacion. http://www.ibt.unam.mx/computo/ pdfs/bioterio.NOM-062.pdf.
  • 39. Okai Y, Higashi-Okai K. 1996. Possible immunomodulating activities of carotenoids in in vitro cell culture experiments. International Journal of Immunopharmacology, 18, 753-758.
  • 40. Park JS, Chyun JH, Kim YK, Line LL, Chew BP. 2010. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & Metabolism, 7(18), 1-10.
  • 41. Pereira AL, Rocha-Rodriguez D, Costa Da Cunha E, Dos-Reis MA, Antunez V. 2002. Morphometric study of the spleen in chronic Chagas disease. American Journal of Tropical Medicine and Hygiene, 66(4), 401-403.
  • 42. Ribeiro MC, Coury PR, Sinfroni FM, Bennedetti PE, Monguillhott DE, Silva FT, Oliveira-Silva D, Colepicolo P, Wilhelm FD. 2010. Antioxidant therapy attenuates oxidative insult caused by benzonidazole in chronic Chagas heart disease. International Journal of Cardiology, 145, 27-33.
  • 43. Rolon M, Vega C, Escario JA, Gomez-Barrio A. 2006. Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes. Parasitology Research, 99, 103-107.
  • 44. Rose S, Misharin A, Perlman H. 2012. A novel Ly6C/Ly6Gbased strategy to analyze the mouse splenic myeloid compartment. Cytometry A, 81(4), 343-350.
  • 45. Rowland CE, Sibley-Phillips S. 1984. Bone marrow eosinophil levels in Trypanosoma cruzi infected mice. Journal of Parasitology, 70(5), 819-820.
  • 46. Silveira AC, Dias JC. 2011. The control of vectorial transmission. Revista da Sociedade Brasileira de Medicina Tropical, 44(2), 52-63.
  • 47. Silveira AC. 2011. New challenges and the future of control. Revista da Sociedade Brasileira de Medicina Tropical, 44(2), 122-124.
  • 48. Uchiyama N, Kabututu Z, Kubata B, Kiuchi F, Ito M, Nakajima-Shimada J. 2005. Antichagasic activity of komaroviquinone is due to generation of reactive oxygen species catalyzed by Trypanosoma cruzi old yellow enzyme. Antimicrobial Agents and Chemotherapy, 49(12), 5123-5126.
  • 49. Ukachi EI, Igoli JO, Onyiriuka SO, Ejele AE, Ogukwe CE, Ayuk AA, Elemo GN, Gray AI. 2015. Antitrypanosomal and antioxidant activities of Moringa oleifera lam leaf extracts. Journal of Pharmaceutical, Chemical and Biological Sciences, 3(1), 17-23.
  • 50. Viotti R, Vigliano C, Lococo B, Alvarez M, Petti M, Bertochi G. 2009. Side effects of benznidazole as treatment of Chagas disease: fears and realities. Expert Review of Antiinfective Therapy, 14(7), 157-163.
  • 51. Wen JJ, Gupta S, Guan Z, Dhiman M, Condon D, Lui C, Garg NJ. 2010. Phenyl-α- tert-butyl-nitrone and benzonidazole treatment controlled the mitochondrial oxidative stress and evolution of cardiomyopathy in chronic chagasic rats. Journal of the American College of Cardiology, 55(22), 2499-2508.
  • 52. WHO. 2017. Chagas disease (American trypanosomiasis). http://www.who.int/mediacentre/factsheets/fs340/en/
  • 53. Zacks MA, Wen JJ, Vyatkina G, Bhatia V, Garg N. 2005. An overview of chagasic cardiomyopathy: pathogenic importance of oxidative stress. Annals of the Brazilian Academy of Sciences, 77(4), 695-715.